HANGZHOU TIGERMED CO. H 1 revenue breakdown overview

HANGZHOU TIGERMED CO. H 1 revenue for the last year amounted to 927.51 M EUR, the most of which — 534.25 M EUR — came from its highest performing source at the moment, Clinical Trial Technical Services, the year earlier bringing 573.77 M EUR. The greatest contribution to the revenue figure was made by China — last year it brought HANGZHOU TIGERMED CO. H 1 542.76 M EUR, and the year before that — 500.94 M EUR.